EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B



Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B



Alimentary Pharmacology & Therapeutics 23(3): 409-419



Aim To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B 'e' antigen-negative chronic hepatitis B.Methods A decision analysis model has been used to perform a cost-effectiveness analysis of lamivudine and adefovir dipivoxil from the perspective of the Spanish Public Health System. Data were obtained from clinical trials.Results For the base-case, the total estimated cost per patient treated with lamivudine or adefovir dipivoxil for 4 years was EURO11 457 and EURO21 939 respectively. Virological response at year 4 for the lamivudine arm was 40.4% and 78.0% for the adefovir dipivoxil arm. The average cost-effectiveness ratio (cost per responding patient at year 4) was EURO28 375 for the lamivudine arm and e28 132 for the adefovir dipivoxil arm. The incremental cost-effectiveness ratio of adefovir dipivoxil vs. lamivudine (cost per additional responding patient with adefovir dipivoxil) was EURO27 872, demonstrating that this cost was slightly lower than the average cost-effectiveness ratios of adefovir dipivoxil or lamivudine. The sensitivity analysis demonstrated that the factors that most influence the cost-effectiveness were the response to adefovir dipivoxil and lamivudine at year 4.Conclusion Long-term treatment with adefovir dipivoxil is a cost-effective strategy in patients with chronic hepatitis B 'e' antigen-negative hepatitis.

(PDF emailed within 0-6 h: $19.90)

Accession: 011907204

Download citation: RISBibTeXText

PMID: 16423000

DOI: 10.1111/j.1365-2036.2006.02767.x



Related references

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance. Drug Design, Development and Therapy 9: 2839-2846, 2016

Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Journal of Hepatology 48(5): 728-735, 2008

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. International Journal of Infectious Diseases 16(3): E152-E158, 2012

Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily. Journal of Hepatology 46(5): 791-796, 2007

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Alimentary Pharmacology & Therapeutics 21(5): 531-537, 2005

Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients. Korean Journal of Hepatology 15(1): 52-58, 2009

Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. Journal of Viral Hepatitis 20 Suppl 1: 40-45, 2013

Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World Journal of Gastroenterology 13(30): 4072-4079, 2007

A randomised double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B Week 52 analysis. Journal of Hepatology 38(Supplement 2): 25-26, April, 2003

The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection. Korean Journal of Hepatology 14(4): 503-512, 2009

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55(10): 1488-1495, 2006

Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil. Zhonghua Gan Zang Bing Za Zhi 19(11): 828-832, 2012

Predicting HBeAg loss by HBV DNA early kinetics and HBV genotype during treatment of HBeAg+ chronic hepatitis B patients with adefovir dipivoxil. Journal of Hepatology 38(Supplement 2): 26, April, 2003

The benefits of adefovir dipivoxil for HBeAg-negative chronic hepatitis B did not persist after discontinuation of treatment. Acp Journal Club 144(1): 4-4, 2006

Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 25(11): 963-977, 2007